Poor
Not Aligned
Patient Risk:
Medium
Summary
Only one core interaction claim (NSAIDs may diminish the antihypertensive effect of ACE-inhibitors) is supported by the provided label section. Multiple other claims about fosinopril exposure, specific adverse effects (e.g., dizziness/lightheadedness), renal impairment, angioedema, GI bleeding, cardiovascular event risks, and dose-threshold/proposed monitoring are not supported by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Ibuprofen can reduce the blood pressure-lowering effect of fosinopril.
DRUG_INTERACTIONS (ACE-inhibitors): 'NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.'
Unsupported Statements
Interactions between ibuprofen and fosinopril can occur due to the way they are processed in the body.
The label excerpt supports consideration of the NSAID/ACE-inhibitor interaction generally, but does not support a specific mechanism/processing statement as written.
Ibuprofen can increase the levels of fosinopril in the blood.
No support in the provided label sections.
Increased fosinopril blood levels from ibuprofen may lead to increased side effects such as dizziness.
No support in the provided label sections.
Increased fosinopril blood levels from ibuprofen may lead to increased side effects such as lightheadedness.
No support in the provided label sections.
Increased fosinopril blood levels from ibuprofen may lead to changes in blood pressure.
The provided label supports diminished antihypertensive effect, but does not support a claim framed around increased fosinopril blood levels.
Fosinopril is an ACE inhibitor used to treat high blood pressure.
No support in the provided label sections (fosinopril is not discussed).
Fosinopril is an ACE inhibitor used to treat heart failure.
No support in the provided label sections (fosinopril is not discussed).
Increased blood pressure from reduced fosinopril effect may increase the risk of cardiovascular events such as heart attack.
No support in the provided label sections.
Increased blood pressure from reduced fosinopril effect may increase the risk of cardiovascular events such as stroke.
No support in the provided label sections.
Taking ibuprofen with fosinopril may increase the risk of renal impairment (kidney damage).
No support in the provided label sections for the specific fosinopril/ACE-inhibitor combination.
Taking ibuprofen with fosinopril may increase the risk of angioedema (a serious allergic reaction).
No support in the provided label sections for this combination.
Taking ibuprofen with fosinopril may increase the risk of gastrointestinal bleeding.
No support in the provided label sections for the specific fosinopril/ACE-inhibitor combination.
The interactions between ibuprofen and fosinopril are more pronounced when taking high doses of ibuprofen (more than 2400 mg per day).
No dose threshold or 'more pronounced' statement for this interaction is present in the provided label sections.
If high doses of ibuprofen are prescribed, blood pressure and kidney function should be monitored closely.
No monitoring instruction specific to this interaction/dose is present in the provided label sections.
Contradictions
Low
AI Statement
Ibuprofen can increase the levels of fosinopril in the blood.
Label Reference
DRUG_INTERACTIONS (ACE-inhibitors) excerpt only addresses diminished antihypertensive effect; it does not support increased fosinopril exposure.
Important Omissions
Label-consistent interaction framing regarding ACE-inhibitor effect: consider interaction when NSAIDs are used concomitantly with ACE-inhibitors (e.g., diminished antihypertensive effect) rather than asserting increased fosinopril blood levels and specific downstream adverse effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple claims attribute specific harms and pharmacokinetic effects (e.g., increased fosinopril blood levels, dizziness/lightheadedness, renal impairment, angioedema, GI bleeding) without support from the provided label excerpts, which could mislead safe use decisions relative to on-label interaction guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported and un-cited claims substantially exceed what is provided in the label excerpt; only diminished antihypertensive effect is supported.
Suggested Improvement
Restrict interaction statements to on-label guidance provided for NSAID/ACE-inhibitor interaction (diminished antihypertensive effect and consideration in concomitant use) and remove unsupported claims about increased fosinopril blood levels, specific adverse effect risks, dose thresholds, and monitoring instructions unless supported in the provided label.